News

Lupin launches tablets in US for Bacterial Infection after getting USFDA nod

Lupin

Lupin launched Doxycycline Hyclate Tablets USP, 75 mg and 150 mg after having received an approval from the United States Food and Drug Administration (USFDA) earlier. The stock was up 3% by the end of the day.

Lupin

Lupin’s Doxycycline Hyclate Tablets USP, 75 mg and 150 mg are the AB rated generic equivalent of Aqua Pharmaceuticals, LLC’s Acticlate Tablets, 75 mg and 150 mg. They are indicated in the treatment of infections caused by various microorganisms and as an adjunctive therapy in severe acne.

Doxycycline Hyclate Tablets USP, 75 mg and 150 mg had annual sales of around USD 263 million in the US, as per IMS MAT June 2017.

Don't be shellfish...Share on Facebook0Share on Google+0Share on LinkedIn0Share on StumbleUpon0Pin on Pinterest0Tweet about this on Twitter0
Click to comment

Leave a Reply

Your email address will not be published. Required fields are marked *

You may use these HTML tags and attributes: <a href="" title=""> <abbr title=""> <acronym title=""> <b> <blockquote cite=""> <cite> <code> <del datetime=""> <em> <i> <q cite=""> <strike> <strong>

Most Popular

To Top